ISCO — International Stem Cell Income Statement
0.000.00%
Last trade - 00:00- $0.88m
- $3.05m
- $9.09m
- 44
- 75
- 56
- 60
Annual income statement for International Stem Cell, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7.13 | 7.18 | 8.18 | 7.79 | 9.09 |
| Cost of Revenue | |||||
| Gross Profit | 4.35 | 4.24 | 4.91 | 4.61 | 5.32 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 9.95 | 7.96 | 8.36 | 8.45 | 9.15 |
| Operating Profit | -2.82 | -0.784 | -0.183 | -0.663 | -0.068 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2.72 | -0.899 | -0.331 | -0.131 | -0.209 |
| Net Income After Taxes | -2.72 | -0.899 | -0.331 | -0.131 | -0.209 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.72 | -0.899 | -0.331 | -0.131 | -0.209 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.72 | -0.899 | -0.331 | -0.131 | -0.209 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.353 | -0.228 | -0.041 | -0.016 | -0.026 |